The efficacy of medium-and long-term immunosuppressive therapy in Crohn's disease
10.3760/cma.j.issn.0254-1432.2012.05.008
- VernacularTitle:克罗恩病长期免疫抑制治疗的疗效
- Author:
Jie ZHOU
;
Jie ZHONG
;
Zhengting WANG
;
Jielu YUAN
;
Xiaojun YU
;
Rong FAN
- Publication Type:Journal Article
- Keywords:
Crohn' s disease;
Drug tolerance;
Immunosuppressive treatment;
Azathioprine
- From:
Chinese Journal of Digestion
2012;32(5):312-315
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo investigate the clinical features and the efficacy of medium-and long-term immune suppression in the treatment of Crohn's disease (CD) in Chinese Han nationality.MethodsThe clinical data and diagnosis methods of 178 CD patients between 2003 and 2010 were analyzed.All patients received predinisone and immune suppression (azathioprine) treatment.The patients were followed up every 2 weeks.Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) were reviewed every 4 weeks.CD activity index (CDAI) was scored every 3 to 6 months.ResultsThe peak age for onset of CD was between 18 to 30 years old,and the mean time from the appearance of symptoms to diagnosis was (8.3±3.7) months.About 34.8％ (62/178 cases) patients had corresponding complications at time of diagnosis due to the progress of the disease.The average dosage of azathioprine was (1.24±0.16) mg/kg,and the total withdrawal rate due to adverse effect was 15％ (25/167 cases).The surgical intervention rate was 15.1％ (22/146 cases) during long-term follow-up.ESR and CRP of patients decreased obviously and tended to normal after 3 months treatment.The CDAI score significantly decreased after 6 months treatment.Conclusions Most Chinese patients had a good tolerance of immune suppression and achieved better medium- and long-term clinical efficacy at the dosage lower than that recommended by European and United States guidelines.
